The clinical outcomes report is important so treatment is not measured exclusively by what occurs during the hospital stay or at hospital discharge. Meaningful recovery is about whether or not there is healing and growth that occurs following the conclusion of structured treatment. Solutions Healthcare’s 2026 Clinical Outcomes Report will take that longitudinal approach, looking at depression, anxiety, substance use, risk factors related to recovery, and protective factors at multiple stages of assessment, including out to one year post-discharge.
This page is organized and approached through the report-first lens of Solutions Healthcare’s already established Clinical Outcomes resource and contains information from a single source of truth for all report information and statistics: Clinical Outcomes Report, July 2026, created by Pacific Analytics.
This report offers a detailed analysis of clients’ self-reported clinical measures from intake to discharge and post-discharge follow-up in 2026. Pacific Analytics, an independent quantitative behavioral health report company, collected the data, analyzed it, and reported the results, the report says.
Why Clinical Outcomes Reports Matter
But patient testimonials or discharge measurement data on their own don’t address the question that clinical outcomes data can answer: Do improvements persist long after treatment?
The 2026 report is focused on reporting treatment effectiveness at Solutions Healthcare specifically for the issues of depression, anxiety, and substance abuse.
Report questions ensured asking whether there were improvements for the treatment over time for each domain. Also, using the BAM-R, the report looked at risk and protective factors related to recovery. This allows for the investigation to be extended beyond the reduction of symptoms. It takes into account a decrease in pressures and an increase of elements that will enable recovery.
Study Methodology
report Design
Through a multipronged approach, the study took a quantitative measure to assess the effectiveness of Solutions Healthcare in improving the well-being of the client.
PHQ-9, GAD-7, and BAM-R data were sampled at and evaluated by report evaluators as follows:
- Intake
- Discharge
- One month post-discharge
- Three months post-discharge
- Six months post-discharge
- One year post-discharge
About 300 clients were selected with entry dates between 15th April 2024 and 27th June 2025. The clients entered treatment with a variety of psychological health and wellness diagnoses, often with comorbidity.
The report includes a sample-response table, demonstrating that the number of assessments completed varied considerably between measures and across time. Of these, BAM-R had 651 intake responses, 712 in PHQ-9, and 731 in GAD-7, and 76, 66, and 47 one-year responses, respectively.
Statistical Method
Changes over time were analyzed with a general linear mixed model (GLMM). This method enables the analysis of data from the participants with missing data in subsequent measurements and is more flexible than a typical repeated measures ANOVA, as the report explains.
This is of significance because there was a decreasing number of follow-up participations over time. Longitudinal information was not lost due to missing one assessment in the mixed-effects approach, which allowed all information to be included.
100% Confidential Support is Available 24/7
No matter what you’re going through, you’re not alone. Our dedicated team is here to provide a safe, judgment-free space where you can talk openly and honestly. Whether you need emotional support, resources, or just someone to listen.
We’re here for you—completely confidential and always respectful of your privacy. Call us today!
Assessment Tools
PHQ-9
The Patient Health Questionnaire-9 contains nine questions used to assess depression severity. The report presents these severity ranges:
PHQ-9 Score | Depression Severity |
0–4 | None-minimal |
5–9 | Mild |
10–14 | Moderate |
15–19 | Moderately severe |
20–27 | Severe |
GAD-7
The Generalized Anxiety Disorder-7 is a seven-item self-report measure of anxiety symptoms.
GAD-7 Score | Anxiety Severity |
0–5 | Minimal |
5–10 | Mild |
10–15 | Moderate |
15–20 | Severe |
BAM-R
The Brief Addiction Monitor-Revised is a 17-item measure covering three domains:
- Substance Use
- Risk Factors
- Protective Factors
Each item is scored from 0 to 4, with higher scores representing more of the measured behavior or factor depending on the domain.
Contact Solutions Healthcare
Battling with Drug and Alcohol Addition? Remember, you are not alone and we are here to help you!
Key Results
Clinical Outcomes Data: 2026
Depression: The mean decreased from 15.450 at intake to 6.786 at one year, which is an approximately 56% reduction (PHQ-9 estimated mean).
Anxiety: The estimated mean at intake was 13.595, and at 1 year it was 6.844, which was an approximately 49.7% reduction.
Substance use: At intake, the estimated mean was 2.635, which decreased to 0.762 at one year (a 71.1% reduction).
Risk factors: The mean BAM-R risk was reduced by 43.7% from 13.573 to 7.642.
Protective factors: The estimated mean of protective factors at intake was 9.319 and went up to 17.197 at 1 year for an 84.5% increase.
Longitudinal models indicated there were statistically significant changes over time in depression, anxiety, substance use, risk factors, and protective factors (all at p < .001).
Depression Outcomes: PHQ-9
A decrease in PHQ-9 scores over time was statistically significant in the depression analysis. On average, clients initiated treatment at a moderate level on the depression scale and were discharged sub-threshold to help non-clinical patients remain free from depression.
PHQ-9 Estimated Mean Scores
Assessment | Estimated Mean | 95% CI |
Intake | 15.450 | 14.803–16.098 |
Discharge | 9.053 | 8.246–9.860 |
One Month | 5.117 | 3.193–7.041 |
Three Months | 3.544 | 0.475–6.614 |
Six Months | 7.071 | 4.816–9.327 |
One Year | 6.786 | 4.568–9.004 |
The estimated mean was lowest at 3 months and rose slightly at 6 months and 1 year yet still fell well short of the intake.
The longitudinal model showed a significant effect of time: F(5, 1377) = 55.53, p < .001. Treatment location also showed a significant effect, F(2, 1377) = 7.57, p = .001, and the time-by-location interaction was significant, F(10, 1377) = 10.19, p < .001.
The report warns about facility differences in the context of client acuity and level of care. PHP/IOP: Palm Coast is nearly all PHP/IOP, with residential treatment included at DeLand and Orlando.
Pairwise Depression Results
Based on the change from intake to discharge and subsequently on post-discharge assessments, PHQ-9 scores were significantly reduced at discharge and each post-discharge assessment. Intake-to-discharge had p < .001, intake-to-one-month p < .001, intake-to-three-months p < .001, intake-to-six-months p < .001, and intake-to-one-year p < .001.
The one-month comparison with discharge and the three-month comparison with discharge were also significant, p = .003 and p = .010, respectively. Differences from discharge were not statistically significant at later times, thus confirming the report’s conclusion that the effectiveness gained during treatment was sustained.
Anxiety Outcomes: GAD-7
A similar trend was observed in an anxiety analysis. Clients with GAD-7 scores in the mild range prior to treatment moved to the severe range of scores after treatment.
GAD-7 Estimated Mean Scores
Assessment | Estimated Mean | 95% CI |
Intake | 13.595 | 13.084–14.107 |
Discharge | 8.963 | 8.359–9.567 |
Three Months | 7.985 | 6.457–9.513 |
Six Months | 5.581 | 3.702–7.460 |
One Year | 6.844 | 4.917–8.771 |
The one-year result is said to be a reduction of ~49.7% from intake.
The mixed-effects model found a significant effect of time: F(4, 1398) = 51.88, p < .001. Location was also significant, F(2, 1398) = 3.55, p = .029, as was the time-by-location interaction, F(8, 1398) = 14.00, p < .001.
The authors note that such variation between locations should not be readily assumed as a direct reflection of differences in treatment effectiveness since the facilities treat different groups of clients or provide various levels of care.
100% Confidential Support is Available 24/7
No matter what you’re going through, you’re not alone. Our dedicated team is here to provide a safe, judgment-free space where you can talk openly and honestly. Whether you need emotional support, resources, or just someone to listen.
We’re here for you—completely confidential and always respectful of your privacy. Call us today!
Substance Use Outcomes: BAM-R
The BAM-R use domain showed substantial improvement following treatment.
BAM-R Use Estimated Mean
Assessment | Estimated Mean | 95% CI |
Intake | 2.635 | 2.356–2.915 |
Discharge | 0.448 | 0.061–0.836 |
One Month | 0.650 | -0 / 1.629 |
Three Months | 1.765 | 0.192–3.337 |
Six Months | 1.367 | 0.435–2.300 |
One Year | 0.762 | -0.265–1.789 |
The change from intake to discharge was -83.0% for the BAM-R Use score (approximately 2.64 to 0.45), and the estimated mean value at one year was 0.76, showing a 71.1% decrease from the intake score.
The BAM-R Use model found a significant effect of time, F(5, 1155) = 18.21, p < .001. The overall treatment-location effect was not significant, F(2, 1155) = 2.02, p = .134, although the time-by-location interaction was significant, F(10, 1155) = 3.83, p < .001.
This distinction matters. Overall changes in substance use over time were identified; however, no difference in substance use was found by facility overall that was statistically significant.
Recovery-Related Risk Factors
The BAM-R Risk Domain measured recovery-related vulnerability and risk factors.
BAM-R Risk Estimated Mean
Assessment | Estimated Mean | 95% CI |
Intake | 13.573 | 13.055–14.092 |
Discharge | 10.210 | 9.491–10.930 |
One Month | 7.882 | 6.064–9.700 |
Three Months | 7.283 | 4.364–10.202 |
Six Months | 8.050 | 6.320–9.781 |
One Year | 7.642 | 5.735–9.548 |
The clinical-attention threshold of the report is 12. Higher than the threshold, the mean risk at intake was 13.573 and post-discharge was 10.210 and did not exceed the threshold at follow-up.
The estimated mean at 1 year was 7.642, a 43.7% reduction from intake.
The model found significant change over time, F(5, 1155) = 25.42, p < .001, a significant location effect, F(2, 1155) = 7.33, p = .001, and a significant time-by-location interaction, F(10, 1155) = 4.78, p < .001.
100% Confidential Support is Available 24/7
No matter what you’re going through, you’re not alone. Our dedicated team is here to provide a safe, judgment-free space where you can talk openly and honestly. Whether you need emotional support, resources, or just someone to listen.
We’re here for you—completely confidential and always respectful of your privacy. Call us today!
Protective Factors
One of the most notable findings in the clinical outcomes report was the growth in BAM-R protective factors.
BAM-R Protective Estimated Mean
Assessment | Estimated Mean | 95% CI |
Intake | 9.319 | 8.846–9.792 |
Discharge | 10.582 | 9.925–11.239 |
One Month | 14.701 | 13.042–16.359 |
Three Months | 16.180 | 13.516–18.843 |
Six Months | 16.317 | 14.738–17.897 |
One Year | 17.197 | 15.458–18.937 |
The one-year score was 17.197 compared to 9.319 at intake, thus increasing by 84.5%.
The report found a significant effect of time, F(5, 1155) = 34.81, p < .001.
Using pairwise comparisons, it was found that scores on the protective factors were significantly higher than the intake scores at one month, three months, six months, and one year post-discharge. The estimated difference for 1 year after intake was -7.879 points (p < .001) or an 84.5% decrease.
What the Clinical Outcomes Data Mean
The report presented together indicates a consistent pattern longitudinally:
- There was a significant reduction in depression symptoms.
- There was a significant reduction in the anxiety symptoms.
- There was a reduction in self-reported substance use.
- Risk factors for recovery went down.
- Recovery factors (protective factors) increased.
- Generally, improvements were observed up to the 1st follow-up visit 1 year after discharge.
It is not just the change in scores between intake and discharge that is telling. This report focused on what steps were taken post-structured treatment. While sample sizes reduced during follow-up and some measures varied, there was a valuable trend: progress made in treatment tended to be maintained during follow-up.
Clinical Implications
For Patients
Clinical outcomes report can offer a fresh perspective to treatment that goes beyond the promise of improvement for those thinking about treatment, anyway. Measurable change in the dimensions of behavioral health and recovery.
The fundamental thing is that the report has a follow-up after patients have been discharged. getting a lower score at discharge is relevant, but if the score improves several months later there is more information on whether there was any maintenance of the gains.
For Providers
Longitudinal measurement offers a method to assess intervention outcomes and to consider if change is meaningful over time for providers of behavioral healthcare. The authors’ incorporation of GLMM thus acknowledges one limitation of behavioral health study: all participants don’t necessarily adhere to all follow-up assessments.
For Program Evaluation
The results also show the importance of assessing the results in various areas. However, there is a lot more to recovery than substance use alone. Risk factors and protective factors are also added to offer context of the context in which recovery takes place and the resources available to continue recovering.
Limitations
Several limitations should be taken into account when interpreting the results of the report:
Sample sizes at follow-up were smaller the longer it was delayed. The completion of assessments at these later follow-up time points was low.
Results were somewhat varied in the post-discharge phase. Not all of the measures had a straight-up improvement trajectory.
There were a variety of populations and treatment levels across treatment locations. Thus, comparisons of location-level differences should be viewed in relation to the acuity of the clients served and the treatment setting in which they are provided, rather than as evidence of how well treatments work in that setting.
Subsequent rates of participation were assessment dependent. The sample-response table illustrates the varying number of observations per measure and at each time point.
Discussion and Conclusion
This 2026 Solutions Healthcare Clinical Outcomes Report offers longitudinal clinical outcomes data for key areas relating to depression, anxiety, substance use, risk factors, and protective factors.
The results are threefold.
Improvement was greater than discharge, first. One-year depression, anxiety, substance use, and risk factor scores were maintained below intake levels and protective factors greater.
Second, the changes were statistically significant. Longitudinal models revealed significant “time” effects in the broad areas of outcomes.
Thirdly, recovery is multi-faceted. Considering together the reduction of symptoms and the decrease in risk and increase in protective factors places the largest emphasis on the overall picture.
The findings of the report are that clients showed tangible gains while in treatment that were significant and endured well after the time of discharge. Also underscores the critical importance of a more longitudinal approach rather than only the change from admission to discharge.
This is the bottom line from the clinical outcomes report conducted in 2026: Instrumenting for change over time is a better understanding of how to assess behavioral health and recovery than a single point in time.
Technical Data Summary
The following condensed tables preserve the principal data elements reported in the PDF while making the statistical findings easier to scan.
PHQ-9 Descriptive Data by Location
Period | Location | Count | Mean | SD | CV |
Intake | Palm Coast | 154 | 9.85 | 6.171 | 62.60% |
Intake | DeLand | 82 | 17.23 | 7.740 | 44.90% |
Intake | Orlando | 476 | 19.27 | 7.369 | 38.20% |
Intake | Total | 712 | 17.00 | 8.113 | 47.70% |
Discharge | Palm Coast | 115 | 8.77 | 6.268 | 71.50% |
Discharge | DeLand | 50 | 9.44 | 6.306 | 66.80% |
Discharge | Orlando | 282 | 8.95 | 6.312 | 70.50% |
Discharge | Total | 447 | 8.96 | 6.289 | 70.20% |
One Month | Palm Coast | 15 | 4.93 | 5.444 | 110.40% |
One Month | DeLand | 10 | 4.30 | 3.653 | 85.00% |
One Month | Orlando | 60 | 6.12 | 6.418 | 104.90% |
One Month | Total | 85 | 5.69 | 5.980 | 105.00% |
Three Months | Palm Coast | 6 | 2.33 | 5.241 | 224.60% |
Three Months | DeLand | 4 | 1.75 | 1.500 | 85.70% |
Three Months | Orlando | 20 | 6.55 | 7.487 | 114.30% |
Three Months | Total | 30 | 5.07 | 6.802 | 134.30% |
Six Months | Palm Coast | 10 | 5.40 | 6.670 | 123.50% |
Six Months | DeLand | 8 | 7.63 | 6.209 | 81.40% |
Six Months | Orlando | 37 | 8.19 | 7.612 | 92.90% |
Six Months | Total | 55 | 7.60 | 7.223 | 95.00% |
One Year | Palm Coast | 19 | 7.74 | 9.654 | 124.80% |
One Year | DeLand | 6 | 4.50 | 4.848 | 107.70% |
One Year | Orlando | 41 | 8.12 | 7.407 | 91.20% |
One Year | Total | 66 | 7.68 | 7.902 | 102.90% |
GAD-7 Descriptive Data by Location
This PDF provides counts, means, standard deviations, and coefficients of variation on location-level GAD-7s for the intake, discharge, three months, six months, and one year. The corresponding overall means for each assessment period are 15.22 at intake and 9.09 at discharge, 7.53 at three months, 5.57 at six months, and 6.96 at one year.
BAM-R Use, Risk, and Protective Domains
The PDF offers descriptive statistics by location for each BAM-R domain, such as the number, average, and standard deviation.
For BAM-R use, total means were 2.29 at intake, 0.29 at discharge, 0.81 at one month, 0.83 at three months, 1.70 at six months, and 1.05 at one year.
For BAM-R risk, total means were 14.34 at intake, 9.90 at discharge, 8.66 at one month, 6.72 at three months, 8.14 at six months, and 7.50 at one year.
Raw descriptive statistics for BAM-R protective factors are means of 7.28 at intake, 9.96 at discharge, 15.15 at one month, 15.78 at three months, 17.24 at 6 months, and 15.66 at 1 year.
The observed differences were the “estimated” marginal means at intake (9.319) and one year (17.197), so the difference shown is 84.5%.
Statistical Model Results at a Glance
Outcome | Time Effect | Location Effect | Time × Location |
PHQ-9 | F(5,1377)=55.53, p<.001 | F(2,1377)=7.57, p=.001 | F(10,1377)=10.19, p<.001 |
GAD-7 | F(4,1398)=51.88, p<.001 | F(2,1398)=3.55, p=.029 | F(8,1398)=14.00, p<.001 |
BAM-R Use | F(5,1155)=18.21, p<.001 | F(2,1155)=2.02, p=.134 | F(10,1155)=3.83, p<.001 |
BAM-R Risk | F(5,1155)=25.42, p<.001 | F(2,1155)=7.33, p=.001 | F(10,1155)=4.78, p<.001 |
BAM-R Protective | F(5,1155)=34.81, p<.001 | F(2,1155)=4.01, p=.018 | F(10,1155)=9.03, p<.001 |
Conclusions:
The Solutions Healthcare Clinical Outcomes Report 2026 highlights 4 key points:
First of all, depression got much better. Estimated levels on the PHQ-9 were about 56% lower at 1 year compared to intake and significantly lower statistically throughout follow-up.
Second, anxiety increased and was not worse than baseline. Intake-estimated GAD-7 scores were restored at 1 year at about 49.7% lower, with the score continuing to be within the mild range.
Third, there were beneficial outcomes related to substance abuse. The use of BAM-R was 71.1% lower at 1 year, and the risk was 43.7% lower at 1 year.
Fourth, protective factors to support recovery got better. BAM-R protective factors had increased by 84.5% at 1 year compared to intake.
The longer-reaching recommendation of the report is that some reasonable improvements were seen in treatment and many of the changes remained well after leaving the specialist services.
If you wish to learn more about Solutions Healthcare’s Clinical Outcomes work, please see the Clinical Outcomes page.
Frequently Asked Questions
1. What is a clinical outcomes report?
Clinical outcomes report evaluates measurable changes in patient health and recovery over time. In the Solutions Healthcare 2026 report, reporters examined depression, anxiety, substance use, risk factors, and clinical and protective factors from intake through one year after discharge.
2. How many clients were included in the 2026 outcomes report?
The report describes approximately 300 clients admitted between April 15, 2024, and June 27, 2025. Because assessments were collected repeatedly, the number of recorded responses is much higher than the number of individual clients.
3. What happened to depression scores after treatment?
Estimated PHQ-9 scores decreased from 15.450 at intake to 6.786 at one year, representing an approximately 56% reduction. The longitudinal effect of time was statistically significant at p < .001.[1]
4. What happened to anxiety scores?
Estimated GAD-7 scores decreased from 13.595 at intake to 6.844 at one year, an approximately 49.7% reduction. The longitudinal model found a significant effect of time, F(4, 1398) = 51.88, p < .001.
5. What were the substance use outcomes?
The estimated BAM-R Use score decreased from 2.635 at intake to 0.762 at one year, representing a 71.1% reduction. The effect of time was statistically significant, F(5, 1155) = 18.21, p < .001.
References
Pacific Analytics. Solutions Healthcare Clinical Outcomes Report 2026. Prepared by Kyle Van Duser, Ph.D., principal reporter and CEO, Pacific Analytics. July 2026. Source: Solutions Healthcare Clinical Outcomes Report 2026
